Skip to main content
. 2022 Feb 22;39(4):1754–1771. doi: 10.1007/s12325-022-02060-1

Fig. 4.

Fig. 4

Average monthly dose per trimester above the recommended dose in patients with NETs. ***p < 0.0001, *p < 0.05; p values calculated using the chi-squared test. LAN Lanreotide autogel, NETs neuroendocrine tumors, OCT octreotide long-acting release